Serum Amino Acid Profiles for Chronic Hepatitis B Patients with MASLD

A 756.3 KB PDF data sheet from figshare, authored by Yanping Lan and last updated in April 2026, presents metabolomic analysis results from serum samples of chronic hepatitis B patients. The study compares patients with and without metabolic dysfunction-associated steatotic liver disease (MASLD), identifying nine significantly upregulated amino acids. The validated panel of nine differential amino metabolites (9-DAM) demonstrated high discriminatory power in discovery and validation cohorts.

Use Cases

• Identifying potential biomarkers for liver disease progression based on the validated 9-DAM panel.
• Comparing metabolic profiles between CHB alone and CHB with MASLD based on the 206 significantly altered metabolites.
• Developing diagnostic classifiers using amino acid signatures, as the 9-DAM panel achieved AUCs of 0.889 and 0.918.
• Investigating correlations between metabolomic signatures and clinical parameters like liver stiffness measurements.

Strengths

• Includes a validation set of 94 samples, supporting the findings from the 47-sample discovery set.
• Identifies a specific panel of nine amino acids (9-DAM) with high discriminatory performance (AUCs up to 0.918).
• Analysis revealed 206 significantly altered metabolites, providing a broad metabolomic context.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is small (756.3 KB), indicating limited scope and likely summary-level data rather than raw measurements.

Provenance

Source

figshare, author Yanping Lan.

Collection Method

Serum samples analyzed using widely targeted and targeted metabolomics.

Freshness

Last updated 2026-04-29 05:37:15; freshness should be verified.